Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

With new treatments in neurology, and more in development in cardiology and autoimmune diseases, precision medicine is moving ...

Injection site reactions, such as bleeding or pain, were common side effects of Zepbound. These reactions should go away on their own within a few days of injecting your Zepbound dose. But ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.